Regulatory approval
Published by the Health Canada.
Health Canada approved larotrectinib for the treatment of adult and pediatric patients with solid tumours that have a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion without a known acquired resistance mutation.
This is written in the approval document as:
VITRAKVI (larotrectinib) is indicated for the treatment of adult and pediatric patients with solid tumours that have a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion without a known acquired resistance mutation.
Citation
Therapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.
| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | v::NTRK1 | Any solid tumor | Larotrectinib | |
| Sensitivity (+) | v::NTRK2 | Any solid tumor | Larotrectinib | |
| Sensitivity (+) | v::NTRK3 | Any solid tumor | Larotrectinib |